EFEMP1 and malignant mesothelioma: In fact, fibulin-3 has been proposed as a clinical biomarker for metastatic ovarian cancer [11] and malignant mesothelioma [14–16], since plasma levels are elevated in these cancer patients compared to healthy controls.